NEW YORK (GenomeWeb News) – Sequenom said this week that the California Technology Assessment Forum has completed an independent evaluation of the cell-free fetal DNA technology used in the Sequenom Center for Molecular Medicine's MaterniT21 Plus laboratory-developed test. According to the firm, CTAF recommended that the use of cell-free fetal DNA as a prenatal advanced screening test for fetal aneuploidy for Trisomy 21 and Trisomy 18 in high-risk women meets all five CTAF criteria for safety and efficacy and improvement in health outcomes.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.